Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 20 de 1371 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Silverman E. STAT Plus: Novartis is the latest big drug maker to exit antibiotic research. STAT Daily Recap 2018:3. [Ref.ID 102708]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Mitjà O, Godornes C, Houinei W, Kapa A, Paru R, Abel H, González-Beiras C, Bieb SV, Wangi J, Barry AE, Sanz S, Bassat Q, Lukehart SA. Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study. Lancet 2018;391:21 de abril. [Ref.ID 102568]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Šmajs D, Pospíšilová P. Macrolide resistance in yaws. Lancet 2018;391:21 de abril. [Ref.ID 102567]
4. Cita con resumen
King LM, Sanchez GV, Bartoces M, Hicks A, Fleming-Dutra KE. Antibiotic Therapy Duration in US Adults With Sinusitis. JAMA Intern Med 2018:26 de marzo. [Ref.ID 102480]
5. Cita con resumen
Zost SJ, Parkhouse K, Gumina ME, Kim K, Díaz Pérez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains . Proceedings of the National Academy of Sciences of the United States of America 2017:6 de noviembre. [Ref.ID 102123]
6. Cita con resumen
7. Cita con resumen
Okano A, Isley NA, Boger DL. Peripheral modifications of [?[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics. Proceedings of the National Academy of Sciences of the United States of America 2017:13 de marzo. [Ref.ID 101615]
8. Cita con resumen
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim Y-S, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr M-B, for the MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017;376:305-17. [Ref.ID 101394]
10. Cita con resumen
Anónimo. Délamanid et tuberculose pulmonaire multirésistante. Prescrire 2017;37:10. [Ref.ID 101359]
12. Cita con resumen
Anónimo. Fosfomycin for UTIs. Drug Ther Bull 2016;54:114-7. [Ref.ID 100882]
13. Cita con resumen
Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]
14. Cita con resumen
Sheldon T. Saving antibiotics for when they are really needed: the Dutch example. BMJ 2016;354:i4192. [Ref.ID 100707]
15. Cita con resumen
Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, García-Basteiro AL, Sevene E, Ballell L, Barros-Aguirre D. ß-lactams against tuberculosis — New trick for an old dog?. N Engl J Med 2016;375:393-4. [Ref.ID 100492]
16. Cita con resumen
Owen J. Pay drug companies $1bn for each new antibiotic, says report. BMJ 2016;353:i2863. [Ref.ID 100427]
19.Tiene citas relacionadas Cita con resumen
Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File Jr TM, Finkelstein JA, Gerber JS, Hyun DY, Linder JA, Lynfield R, Margolis DJ, May LS, Merenstein D, Metlay JP, Newland JG, Piccirillo JF, Roberts RM, Sánchez GV, Suda KJ, Thomas A, Woo TM, Zetts RM, Hicks LA. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 2016;315:1864-73. [Ref.ID 100224]
Seleccionar todas
 
 1 a 20 de 1371 siguiente >>